Health Technology · Pharmaceuticals: Major · NSE: AMBALALSA · data 2026-10-09
Ambalal Sarabhai Enterprises Limited
Health check: Strong (6.6/10 on quality, valuation vs sector, growth and momentum).
Open full analysis — chart, results, balance sheet, red flags →Key figures
Price
₹40.59
Market cap
₹316 cr
P/E
23
P/B
—
ROE
11.9%
ROCE
9.4%
Debt / equity
0.36
Dividend yield
0.00%
1-year return
25.7%
52-week high
₹49.98
52-week low
₹30.15
Operating margin
5.1%
Growth
| Revenue (last 12 months) | ₹206 cr |
| Net profit (last 12 months) | ₹14 cr |
| Sales growth, 3 years (yearly) | 5.9% |
| Profit growth, 3 years (yearly) | 15.9% |
Similar companies
Albert David Ltd (ALBERTDAVD) · Medicamen Biotech Limited (MEDICAMEQ) · Jenburkt Pharmaceuticals Ltd (JENBURPH) · Aarey Drugs & Pharmaceuticals Ltd. (AAREYDRUGS) · Brooks Laboratories Limited (BROOKS)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open AMBALALSA in NSE Scanner →